New modalities (therapeutic approaches) such as antibody-drug conjugates (ADCs), obesity drugs, and gene-editing technologies need dramatic regulatory relief to settle in Korea, said experts.

On the 14th, KoreaBio held a seminar on trends and prospects of the bio-industry at the El Tower in Seocho-gu, Seoul. At the event, Seung-Kyou Lee, Vice President of KoreaBio, presented his assessment of the bio-industry this year and its prospects.

Lee cited gene therapy drugs, obesity and diabetes drugs, and ADCs as new modalities that the Korean pharma-bio industry is interested in and developing.

With the recent commercialization of gene therapy drugs such as Exa-cel, and Lyfgen